Tracking Utilization of Neoadjuvant Endocrine Therapy (NET) and Neoadjuvant Chemotherapy (NCT) for Hormone Receptor-Positive Breast Cancer (HR + BC) in the U.S.A. Over Time - A TriNetX Database Study.

Global Burdens and Trends of Breast Cancer Attributable to Dietary and Metabolic Risks: A 30-Year Analysis With Projections to 2050, Including Males and Females.

Severe Adverse Events in Neoadjuvant Therapy of Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Phase 3 Trials.

Clinical and Demographic Characteristics of Patients With Long-Term Disease Control With First-Line Endocrine Therapy Alone for Hormone Receptor Positive, HER2 Negative, Metastatic Breast Cancer.

Clinical Characteristics and Cancer Histories Among Breast Cancer Patients With Li-Fraumeni Syndrome From a Single Institution.

Methodological Concerns Regarding the Assessment of Breast Cancer Risk Following Gender-Affirming Care.

Tracking Utilization of Neoadjuvant Endocrine Therapy (NET) and Neoadjuvant Chemotherapy (NCT) for Hormone Receptor-Positive Breast Cancer (HR + BC) in the U.S.A. Over Time - A TriNetX Database Study.

Global Burdens and Trends of Breast Cancer Attributable to Dietary and Metabolic Risks: A 30-Year Analysis With Projections to 2050, Including Males and Females.

Severe Adverse Events in Neoadjuvant Therapy of Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Phase 3 Trials.

Clinical and Demographic Characteristics of Patients With Long-Term Disease Control With First-Line Endocrine Therapy Alone for Hormone Receptor Positive, HER2 Negative, Metastatic Breast Cancer.

Clinical Characteristics and Cancer Histories Among Breast Cancer Patients With Li-Fraumeni Syndrome From a Single Institution.

Methodological Concerns Regarding the Assessment of Breast Cancer Risk Following Gender-Affirming Care.